Huafu Securities released a research report on April 16 stating that Ma Yinglong (600993.SH) was given a buying rating. The main reasons for the rating include: 1) full-year and Q4 performance was under pressure, with non-net profit falling by more than 20%; 2) pharmaceutical industry: optimizing the inventory structure, smooth channel sorting, and a sharp drop in core product inventory; 3) Service and commerce: an important fulcrum for building Ma Yinglong's entire anorectal industry chain. (Mainichi Keizai Shimbun)
华福证券4月16日发布研报称，给予马应龙（600993.SH）买入评级。评级理由主要包括：1）全年和Q4业绩承压，扣非净利下滑超两成；2）医药工业：优化存量结构，渠道梳理顺畅，核心产品库存大幅下降；3）服务与商业：打造马应龙肛肠全产业链的重要支点。（每日经济新闻）
Huafu Securities released a research report on April 16 stating that Ma Yinglong (600993.SH) was given a buying rating. The main reasons for the rating include: 1) full-year and Q4 performance was under pressure, with non-net profit falling by more than 2
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated